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was greatly reduced in five out of six cell lines compared to their respective parental cell lines (Fig. 1b ). This observation was further corroborated by the IHC staining of p-ERK(T202/Y204) in paired pre-and post-treatment tumour biopsy specimens from eight patients on BRAFi and MEKi combination therapy. p-ERK(T202/Y204) was increased in one out of eight post-treatment tumour biopsy specimens, but was reduced or remained low in the remaining specimens ( Fig. 1c , Extended Data Fig. 1b and Supplementary Tables 1, 2) . We also analysed p-ERK activity in tumour samples of combination therapy-resistant patient-derived xenografts (CRPDX) that were implanted in different mice. ERK was not reactivated when these mice were treated with BRAF and MEK inhibitors (Extended Data Fig. 1c ). The data suggest that the mechanisms underlying CR are different from those that induce BR in many patients.
We detected increased levels of phosphorylated CRAF (p-CRAF(S338)) in most of the acquired drug-resistant cell lines, similar to previous studies 13 (Fig. 1d, e ). CRAF is directly phosphorylated by PAKs at serine 338 (S338) 15, 16 . We found that PAKs were activated in most of the resistant cells and CRPDX tumour samples (Fig. 1d , e and Extended Data Fig. 1c, d ). PAKs are serine/threonine protein kinases that function downstream of the small GTPases CDC42 and RAC1, and are involved in many tumorigenic pathways 17 . CDC42 and RAC1 show increased expression in some BR and CR cell lines (Extended Data Fig. 1e ). Quantitative real-time PCR with reverse transcription (RT-qPCR) analysis shows that the expression of PAK1, PAK2, RAC1 and CDC42 was increased in post-treatment tumour biopsies that were derived from eight patients with metastatic melanoma treated with either BRAFi or BRAFi and MEKi (Fig. 1f ). In addition, gene set enrichment analysis of RNA-sequencing data derived from paired pre-and post-treatment tumour biopsy specimens of six patients and the public database 5, 18 showed PAK signalling activation in most of the tumour biopsies with acquired resistance to MAPK inhibitors (Extended Data Fig. 1f-1k and Supplementary Table 3 ).
It has been previously reported that parental melanoma cells with the BRAF V600E mutation are insensitive to the inhibition of PAKs 19 . Here we found that, unlike parental cells, both BR and CR cells became sensitive to the PAK inhibitor PF-3758309 (ref. 20 ; Fig. 2a and Extended Data that PAK inhibition slowed cell-cycle progression with more cells arrested in the G0/G1 phase (Extended Data Fig. 4 ). We also inhibited PAK1 function by RNA interference (RNAi), expression of the kinase-dead mutant of PAK1 (PAK1 K299R ) and the PAK auto-inhibitory domain (PAK1 PID ), or by adding the PAK inhibitor IPA-3. All of these approaches led to suppression of the viability of BR and CR cells ( Fig. 2b, Extended Data Fig. 5a-f and Supplementary Table 4 ). Conversely, ectopic expression of the constitutively active mutant of PAK1 (PAK1 107F/423E ) conferred drug resistance to MAPK inhibitors in parental 1205Lu cells (Fig. 2c ). In addition to targeting PAK1, RNAi-mediated silencing of PAK4, a member of the group II PAKs, also inhibited the growth of BR and CR cells (Extended Data Fig. 5g -i). In mice, tumour xenografts of WM4008-1 (CRPDX) and other BR and CR cell lines were sensitive to PAK inhibition ( Fig. 2d and Extended Data Fig. 6 ), suggesting that PAKs have a pivotal role in the survival of therapy-resistant melanoma when the MAPK pathway is blocked.
PAKs are able to activate ERK by directly phosphorylating CRAF at S338 and MEK at S298 (refs 15, 16) . We found that both p-CRAF(S338) and p-MEK(S298) were significantly increased in BR cells (Fig. 3a) , and PF-3758309 downregulated MAPK signalling in BR cell lines ( Fig. 3b ) and 1205Lu-BR xenografts (Fig. 3c ). To gain a comprehensive understanding of the signalling pathways that were altered in BR cell lines upon PAK inhibition, we treated BR cell lines, including those established from BR patient-derived xenografts (BRPDX) with PF-3758309 and profiled them using a reverse-phase protein array ( Fig. 3d and Extended Data Fig. 7a ). Several major changes were detected with PF-3758309 treatment: (1) inhibition of the MAPK pathway, as indicated by the decrease in p-ERK(T202/Y204) and its downstream target p-c-JUN(S73) (also known as p-JUN(S73)); (2) inhibition of cell-cycle progression as shown by the decrease in FOXM1, cyclin B1 and CDK1, concurrent with the decrease in p-Rb(S807/S811); (3) inhibition of mTOR signalling as indicated by the decrease in p-S6(S235/S236), p-S6(S240/S244), p-4E-BP1(S65) and p-4E-BP1 (T37/T46). We also examined the effect of expressing constitutively active PAK1 in the parental cell line 1205Lu using a reverse-phase protein array and immunoblotting. PAK1 107F/423E had limited effect on cells in the absence of PLX4720, but blunted the inhibitory effect of PLX4720 on p-MEK1(S217/S221), p-ERK(T202/Y204), p-S6(S235/S236 and p-S6(S240/S244) ( Fig. 3e, f) .
For CR cells, PF-3758309 did not significantly affect the phosphorylation of ERK as was observed in BR cells, but inhibited the downstream targets of ERK, p-ELK1(S383) and p-RSK(T359/S363). In addition, mTOR pathway activity was mostly inhibited as indicated by the decrease in both p-4E-BP1 and p-S6 ( Fig. 4 and Extended Data Fig. 7b , c). Expression of the active PAK1 107F/423E in 1205Lu parental cells did not lead to ERK reactivation in response to PLX4720 and PD0325901, but instead promoted cell-cycle progression, as indicated by the increase in p-Rb and p-cyclin B1. Furthermore, the decrease in BIM and BAX in cells expressing constitutively active PAK1 indicated that apoptosis was inhibited (Extended Data Fig. 7d ). Together, our analyses showed that PAKs mediate CR through at least four pathways: (1) PAK activation is required for sustained JNK activity. Because JNK and ERK have common downstream targets such as ELK1, JUN and FOS 21, 22 , JNK activity may partially compensate for the lack of ERK activation.
(2) Activated PAKs and CRAF phosphorylate BAD, which blocks
WM989-BR SK-MEL-28 SK-MEL-28-BR p-PAK1(S199/S204) p-PAK2(S192/S197) p-CRAF(S338) p-PAK1(S199/S204) p-PAK2(S192/S197) Fig. 4 and Extended Data Fig. 7 ). Compared with parental and BR cells, CR cells were more sensitive to JNK and S6K inhibitors, but less responsive to the ERK inhibitor, which is consistent with a recent study 13 (Extended Data Fig. 8a, b ). Similarly, silencing JNK and β -catenin by short-hairpin RNA inhibited CR cell viability (Extended Data Fig. 8c-e ).
Our study reveals mechanisms that underlie acquired drug resistance to both BRAFi and combined BRAFi and MEKi therapies, and provide insight into the rewiring of the signalling networks in BR and CR cells (Extended Data Fig. 8f ). This study highlights PAKs as pivotal mediators of drug resistance, and potential therapeutic targets for treating patients whose tumours progress on these targeted therapies. letter reSeArCH
MethOdS
Cell culture, reagents, plasmids and antibodies. All human metastatic melanoma cell lines were established at The Wistar Institute as previously described 25 . They were authenticated by DNA fingerprinting and were tested regularly before assays to avoid mycoplasma contamination. All melanoma cell lines were cultured in RPMI 1640 (Invitrogen) supplemented with 5% FBS. Resistant cells were maintained with PLX4720 at 3 μ M for BR cells and BRPDX cells or the combination of PLX4720 at 3 μ M plus PD0325901 at 300 nM for CR cells throughout the experiments. 1205Lu cells stably expressing the vector control or PAK1 L107F/T423E mutant were selected using 1 μ g ml −1 puromycin for 10 days. DNA and RNA transfection were conducted using Lipofectamine2000 (Invitrogen), Fugene 6 (Roche) or Lipofectamine RNAiMAX (Invitrogen). The human PAK1 siRNA sequence was 5′ -GAAGAAATATACACGGTTT-3′ ; the PAK2 siRNA sequence was 5′ -AGAAGGAACTGATCATTAA-3′ (ref. 26 ) and the control luciferase GL2 siRNA sequence was 5′ -AACGTACGCGGAATACTTCGA-3′ . Short hairpin RNA (shRNA) targeting JNK1, JNK1/2 and CTNNB1 (β -catenin) were provided by S. Andreadis (University of Buffalo) and Z. Lu (M.D. Anderson) [27] [28] [29] .
The shRNA clones targeting PAK4 were ordered from Sigma-Aldrich: 5′ -GAGCCACAGCGAGTATCCCAT-3′ , 5′ -CGAGAATGTGGTGGAGATGTA-3′ and 5′ -GACTCGATCCTGCTGACCCAT-3′ . PLX4720 and PD0325901 were provided by Plexxikon. PF-3758309 was provided by Pfizer. MEK162, LGX818, GSK2118436, GSK1120212, GDC0973 and PLX4032 were purchased from Selleckchem. Human kinase-dead PAK1 K299R , PAK1 PID mutant and constitutively active PAK1 L107F/T423E mutant were cloned into the pCMV6 or pBabe PURO vector. All constructs were confirmed by sequencing. All information about the primary antibodies is included in Supplementary Table 5 . Secondary antibodies were purchased from Invitrogen or GE Healthcare. RNA extraction and RT-qPCR. Total RNA was extracted using Trizol (Invitrogen) according to the manufacturer's instructions. cDNA synthesis was performed with the M-MLV Reverse Transcriptase Kit (Promega). RT-qPCR was performed using the Fast SYBR Green Master Mix Kit (Life Technologies). Amplifications were performed using an Applied Biosystems 7500 Real-Time PCR System (Life Technologies). All experiments were performed in triplicate. Expression ratios of controls were normalized to 1. Oligonucleotide primers used in RT-qPCR: PAK1, GCTGTTCTGGATGTGTTGGA and TTCTGAAACTGGTGGCACTG; PAK2, ACAGAAGCACCCGCAGTAGT and AAAGACTTGGCAGCACCATC; PAK4, CAGGGAAGGCAGGCAGCCGA and CCTGTCACCACTGCCGCCAC; RAC1, CAATGCGTTCCCTGGAGAGTACA and ACGTCTGTTTGCGGGTAGGAGAG; CDC42, TAACTCACCACTGTCCAAAGACTCC and CCTCATCAA ACACATTCTTCAGACC; GAPDH, GAAGGTGAAGGTCGGAGTC and GAAGATGGTGATGGGATTTC. Cell viability, cell cycle and apoptosis assay. Cell viability was analysed by Giemsa staining. In brief, equal numbers of cells were seeded at approximately 40% confluency in six-well plates and treated with DMSO or the indicated inhibitors. The cells were then washed with PBS and fixed with methanol and acetone (1:1), and stained with Giemsa solution (Millipore) for 30 min. The cell density was measured using Adobe Photoshop or ImageJ. The values after background subtraction were normalized to the control group. The MTT assay was performed using the Cell Proliferation Kit I (Roche) according to the manufacturer's instructions. The IC 50 values were calculated from dose-response curves using Graphpad Prism 5.
For the apoptosis assay, BR and CR cells were treated with DMSO or PF-3758309 for 72 h. Cells were resuspended in 0.1 ml PBS after centrifugation, and then co-stained with propidium iodide (Sigma-Aldrich) at 1 μ g ml −1 and PSVue 643 (Molecular Targeting Technologies) at 5 μ M. Cell suspensions were kept in the dark at room temperature for 5 min. Subsequently, 0.2 ml PBS with 10% FBS was added to each cell suspension, and the cells were immediately analysed using a BD LSRII flow cytometer. For the cell-cycle analysis, BR and CR cells were treated with DMSO or 1 μ M PF-3758309 for 48 h. Control or treated cells were fixed with ice-cold 100% EtOH for 20 min, stained with propidium iodide and subsequently analysed using a FACSCalibur. FSC and SSC gating was used to select single cells for the cell-cycle analysis. The G0/G1 peak was centred at the PI/FL-2H Channel = 200, using cells that were within the specified FL2-A/FLW gate. FCS files were then analysed after collection using ModFit software. Events that were in both the FSC/SSC and within the FL-2A/FL-2W gates were analysed to determine the percentage of cells in each stage of the cell cycle (PI/FL-2H). Reverse-phase protein array. The reverse-phase protein array (RPPA) assay was performed by the M.D. Anderson Cancer Center core facility using 50 μ g protein per sample. Antibodies were validated by western blotting 30 . The RPPA data have been submitted to the Gene Expression Omnibus public database at the National Center for Biotechnology Information, following the information about RPPA experiment guidelines. The accession codes are GSE96902 and GSE96753. IHC staining. IHC staining was performed on formalin-fixed, paraffin-embedded sections. Antigen retrieval was performed by steaming the slides in citrate buffer for 5 min (pH 6.0). Sections were incubated with anti-p-ERK (1:100; Cell Signaling) antibody overnight at 4 °C, followed by incubation with a biotinylated secondary antibody (1:200; Jackson Immuno Research) for 30 min. Detection was performed using Nova Red or DAB (Fisher Scientific). The pathologist who examined the tumour sections was blinded to the clinical treatment information. There were no identifiable images of human research participants. , individually or in combination, was started when the tumour volume in mice reached ~ 100 mm 3 . Tumour volume was calculated using the formula: tumour volume = length × width × width/2. The mice were subjected to continued treatment until the tumour reached 10% of the body weight or reached the limit of the allowed tumour dimensions. For single tumours, growth was limited to a diameter of 2.0 cm (or a volume of 4.2 cm 3 ) at the widest point as long as the mouse remained healthy. For multiple tumours in a mouse, tumour growth was limited to a total diameter of 3.0 cm (the limit for any of the single tumour was still 2.0 cm). Throughout the experiments, all of the mice were carefully monitored at least twice a week for signs of distress, and were euthanized when they were determined to have poor body condition scores. Mice that died or with tumour sizes that reached the dimension limit set by Penn IACUC guidelines shortly after the start of the procedure were excluded from statistical analysis. No statistical methods were used to predetermine sample size. Statistical analyses and reproducibility. RPPA data analysis was performed according to the protocol from the M.D. Anderson Cancer Center. Specifically, relative protein levels for each sample were determined by interpolation of each dilution curves from the standard curve (supercurve) of the slide (antibody). Supercurve is constructed by a script in R written by the RPPA core facility. These values are defined as the Supercurve log 2 value. All data points were normalized for protein loading and transformed to a linear value, designated as 'normalized linear' . The normalized linear value was transformed to a log 2 value, and then median-centred for further analysis. Median-centred values were centred by subtracting the median of all samples in a given protein. All of the above-mentioned procedures were performed by the RPPA core facility. The normalized data provided by the RPPA core facility were analysed using the LIMMA package in R. In Extended Data Fig. 7a , we show proteins with significant changes (false discovery rate is controlled at the 0.01 level by using the Benjamini-Hochberg procedure for multiple-comparison correction) in at least four BR cell lines out of the nine BR cell lines after PF-3758309 treatment versus DMSO. Similarly, in Extended Data Fig. 7b , we show the proteins with significant changes in at least two CR cell lines out the three CR cell lines after PF-3758309 treatment versus DMSO.
The microarray data were analysed with the lumi package in the R/Bioconductor environment 7 . The probes were filtered to include genes with a detection value of P < 0.05 in all samples for use in further analyses. The data was transformed by variance-stabilizing transformation (VST) and then normalized by quantile normalization using the lumi package. The microarray data of genes of interest, including PAKs, RAC1 and CDC42, were extracted and subsequently visualized in heat maps using the heat map.2 program within the gplots package of R.
The enrichment score (Extended Data Fig. 1g , i, k) was generated using the single-sample GSEA (ssGSEA) method 32 . The enrichment score analysis was carried out using GSVApackage in R 33 . The enrichment score in the ssGSEA letter reSeArCH method essentially is the weighted sum of the difference between the empirical cumulative distribution functions of the genes within the gene signature and the remaining genes.
All other statistical analyses were performed using R, version 2.14. Two-way ANOVA (mouse tumour volumes) and log-rank test (mouse survival) were used to compare data between PLX4720 or PLX4720 with PD0325901 and all other groups, no multiple comparisons. Two-sided Student's t-tests were used for pairwise comparison of the remaining datasets. Data availability. RPPA data are available from the NCBI Gene Expression Omnibus (GEO) under accession numbers GSE96902 and GSE96753. Patient information is provided in Supplementary Table 1 . Information for p-ERK IHC staining is provided in Supplementary Table 2 . Information for patients with PAK-pathway activation is provided in Supplementary Table 3 . IC 50 values for MTT assays are provided in Supplementary Table 4 . Antibody information is provided in Supplementary Table 5 . All mouse data are provided in Supplementary Table 6 . The number of times the experiments have been completed independently with similar results is listed in Supplementary Table 7 . For immunoblot source data, see Supplementary Fig. 1 . Source Data are provided for all graphs. All of the data are available from the authors upon reasonable request.
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Extended Data Figure 1 | ERK and PAK activity in BR and CR melanoma. Related to Fig. 1. a, b , IHC staining of p-ERK(T202/Y204) in paired pre-and post-treatment tumour biopsy specimens acquired from patients who relapsed on BRAFi (a) or combined BRAFi and MEKi (b) treatment. Note that some of the strongly positive-stained cells are macrophages rather than tumour cells. Scale bars, 50 μ m. The tissues were stained with Nova Red. c, Western blotting analysis of the levels of p-ERK T202/Y204 and p-PAK1(S199/S204)/PAK2(S192/S197) in WM3939 CRPDX tumour samples. Tumours from mice treated with vehicle control or with BRAFi and MEKi are shown. WM9-CR was used for comparison. d, Western blotting of PAK phosphorylation in matching parental, BR and CR cells. e, Western blotting using a polyclonal antibody that recognizes both CDC42 and RAC1 in matching parental, BR and CR cells. CDC42 and RAC1 could not be separated by SDS-PAGE owing to their similar molecular weights. f, h, j, Heat maps of expression levels of PAKs, RAC1
and CDC42 in paired pre-and post-treatment tumour biopsy specimens acquired from patients with metastatic melanoma who progressed on MAPK inhibitors. Data were analysed using the LIMMA package in R. The fold change of expression levels in a paired post-treatment tumour biopsy specimen over the pre-treatment tumour biopsy specimen is shown in the heat map. Colour scale, the log 2 -transformed expression of each gene was normalized to the mean value of all samples. g, i, k, Heat maps of the enrichment scores of two PAK signalling-related gene sets in paired pre-and post-treatment tumour biopsy specimens acquired from patients with metastatic melanoma who relapsed on MAPK inhibitors. The value for each entry is the difference in enrichment score of post-treatment over pre-treatment specimens. Gene expression microarray or RNA-sequencing data were downloaded from EGAD00001001306, GSE65184, GSE65185 and GSE61992. Supplementary Table 4 . Two-sided Student's t-tests were used for statistical analyses of the IC 50 values. e-h, Seven BR (e) and six CR cell lines (f) were treated with DMSO, 1 μ M or 3 μ M PF-3758309 for 72 h, and then fixed and stained with Giemsa. The data are shown in g for BR cells and in h for CR cells (n = 3 biologically independent samples). The cell density was measured using ImageJ software (NIH). The values after background subtraction were normalized to cells treated with DMSO. Two-sided Student's t-tests were used for statistical analyses (b-d, g, h) . Data are plotted as mean ± s.e.m. Fig. 2.  a, b , Relative survival of BR and CR cells treated with increasing concentrations of the PF-3758309 (PF), PLX4720 (PLX) and PD0325901 (PD) for 48 h. Cell viability was analysed by MTT assay. The data were normalized to cells treated with DMSO (n = 4 biologically independent samples). c, FACS analysis of BR cells and CR cells treated with PF-3758309. All cells were labelled with propidium iodide and PSVue 643, and analysed using a BD LSRII. d, Quantification of cell apoptosis. The percentage of apoptosis cells after PF-3758309 treatment was compared to cells treated with DMSO (n = 3 or 4 biologically independent samples as indicated). e, g, Giemsa staining of BRPDX cell lines WM3936 and WM3903 that were treated with DMSO, or different concentrations of PF-3758309 for three days. The quantification of the staining is shown in g (n = 3 biologically independent samples). f, h, Anchorage-independent growth assay of WM3936 cells. A total of 2,000 cells were seeded in medium with soft agar in six-well plates. Scale bar, 200 μ m. The number of colonies in each field is quantified in h (n = 6 biologically independent samples). i, WM3936 cells were treated with DMSO or different concentrations of PF-3758309 for three days. All cells were labelled with propidium iodide and PSVue 643, and then analysed using a BD LSRII. j, Quantification of cell apoptosis. The percentage of apoptosis cells after PF-3758309 treatment was compared to cells treated with DMSO (n = 5 biologically independent samples). Two-sided Student's t-tests (a, b, d, g, h, j) were used for statistical analyses. Data are plotted as mean ± s.e.m. Fig. 2. a, b , Relative survival of BR or CR cells transfected with PAK1 K299R or PAK1 PID , or siRNA against PAK1 and PAK2. Cells were then cultured with PLX4720 or PLX4720 and PD0325901 at different concentrations for 48 h. Cell viability was analysed by MTT assays (n = 4 biologically independent samples). Two-sided Student's t-tests (for IC 50 values) were used for statistical analysis. c, d, PAK1 and actin levels in cells were analysed by western blotting. e, BR and CR cells were treated with DMSO, 10 μ M or 20 μ M IPA-3 for 72 h, and then processed for Giemsa staining. Fig. 2. a, b , Tumour growth curves. Mice were injected with 1205Lu-BR (n = 9 mice per group) or WM9-BR (n = 9 mice per group) cells (a), WM9-CR (n = 5 mice per group) or A2058-CR (control n = 8, other n = 9 mice per group) cells (b), and proceeded for MAPK or PAK inhibition for the indicated number of days. c, Survival curves of mice bearing 1205Lu-BR and WM9-CR xenografts (n = 5 mice per group). All groups were compared to the PLX or PLX and PD group; no multiple comparisons. Two-way ANOVA (a, b) or log-rank test (c) were used for statistical analyses. Individual tumour volume data points can be found in the Source Data. Data are plotted as mean ± s.e.m. For mouse survival, the function survdiff from the survival R package was used. 4 . a, BR cell lines and BRPDX cell lines were treated with DMSO or PF-3758309 for 48 h. Protein lysates from these cells were then analysed by RPPA. Data were analysed using the LIMMA package in R. The levels of identified proteins (that displayed significant changes in at least four BR cell lines after PF-3758309 treatment versus DMSO, P < 0.01) are shown in the heat map. Colour scale, log 2transformed expression for each protein was normalized to the mean value of all samples. b, 1205Lu-CR, UACC903-CR and WM164-CR cells were treated with DMSO or PF-3758309 for 48 h. Cell lysates were analysed by RPPA. Data were analysed using the LIMMA package in R. The levels of identified proteins (that displayed significant changes in at least two CR cell lines after PF-3758309 treatment versus DMSO, P < 0.01) are shown in the heat map. Colour scale, log 2 -transformed expression (red, high; blue, low) for each protein was normalized to the mean value of all samples. c, 1205Lu and UACC903 parental and CR cells were treated as indicated (Fig. 4b) . Protein levels were analysed in three independent assays, and the staining was measured by ImageJ. (n = 2 for p-ELK1(S383) and p-BAD(S112), n = 3 for all other proteins). To minimize variation caused by different exposure time in each independent assay, the staining was normalized to the mean of all samples from the same group before statistical analyses. Two-sided Student's t-tests were used for statistical analyses. Data are plotted as mean ± s.e.m. d, 1205Lu cells stably expressing PAK1 107F/423E or vector control were treated with 1 μ M PLX4720 and 100 nM PD0325901 for 48 h. The levels of MAPK pathway-related proteins, cell-cycle-related proteins and apoptosis-related proteins were analysed by western blotting. Corresponding author(s): Herlyn, Xu, Guo
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Data exclusions
Describe any data exclusions.
In the mouse studies, the mice that died shortly after procedure or those with tumor burden reached U. Penn IACUC dimension guideline at early stage of treatment were excluded. For other experiments, all data were included.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts to replicate the experiments were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice were allocated randomly to each treatment group. For the other experiments, all data were included.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to the group allocation during the experiments as different drug treatments need to be administered. However, the pathologist who examine the tumor was blinded to the treatment groups.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). Describe the software used to analyze the data in this study.
software R, version 2.14 For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Except for the chemicals that were obtained from certain companies under agreements, all unique materials are available for distribution from the authors or companies.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Antibody information including catalog numbers and clone numbers are shown. More information is provided in the company websites. c. Report whether the cell lines were tested for mycoplasma contamination.
All the cell lines presented in this study were tested for mycoplasma contamination and they were free of mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
None.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study. 
Data presentation
For all flow cytometry data, confirm that:
1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
3. All plots are contour plots with outliers or pseudocolor plots.
4.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodological details 5 . Describe the sample preparation.
For the apoptosis and cell death assay, BR and CR cells were treated with DMSO, 3μM or 5μM PF3758309 for 72 hr. All cells were labeled with propidium iodide and PSVue 643, and then analyzed by BD LSRII. Cells used in cell cycle analysis assays, BR and CR cells ,were treated with DMSO or 1μM PF3758309 for 48 hr. Treated cells and controls were then stained with propidium iodide, and subsequently analyzed using a FACSCalibur.
6. Identify the instrument used for data collection. A BD LSRII was utilized for analysis of apoptosis and cell death. A FACSCalibur was used for cell cycle analysis.
7. Describe the software used to collect and analyze the flow cytometry data.
DIVA software was used for collecting events on the LSRII. Apoptosis and cell death assay flow cytometric data was analyzed using FloJo software. We used CellQuest software to collect cell cycle data on the FACSCalibur. We used ModFit software for post collection analysis of FCS files.
Describe the abundance of the relevant cell
populations within post-sort fractions.
N/A. 9. Describe the gating strategy used. FSC and SSC gating was used to select the cells for PI analysis for cell cycle analysis. The G0/G1 peak was centered at the PI/FL-2H Channel=200 using cells that were within the FSC/SSC gate and within the specified FL2-A/FL-W gate. FCS files were then analyzed post-collection using ModFit software. Events that were in both the FSC /SSC and within the FL-2A/ FL-2W gates were analyzed to determine the % of cells in each stage of the cell cycle(PI/FL-2H).
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
